NewAmsterdam Pharma
NewAmsterdam Pharma Company Logo
About NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral small molecule therapies for cardiovascular and metabolic diseases. Its lead asset, obicetrapib, is an oral CETP inhibitor in clinical trials for lowering LDL-C and reducing cardiovascular risk. The company aims to address unmet needs in lipid-related conditions and serves patients in the US and Europe.
Address
Gooimeer 2-35,
Naarden, 1411 DC
Netherlands
Year founded
2022
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
